New guidelines for blood cancer therapy

23 March 2009

The National Comprehensive Care Network, an alliance of 21 of the world's leading cancer centers, released new guidelines for the  treatment of blood cancers at the NCCN annual conference. Included in  the updated guidelines is a recommendation for Campath (alemtuzumab),  German drug major Bayer's treatment for chronic lymphocytic leukemia, as  a first-line therapy for high-risk CLL patients 70 years old and above.

These are the latest in a series of clinical recommendations recognizing  the importance of personalized medicine in CLL. Over the past few years,  the NCCN treatment guidelines have shifted due to advances in clinical  knowledge about diagnostic markers and targeted therapies, allowing  physicians to personalize treatment for each patient and improve  outcomes. These guidelines support the notion that individualized  therapy is the future of CLL treatment and other blood cancers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight